[Newsmp] Korean pharmaceuticals are struggling even in the new year.
As the slump continued in February, the market capitalization of 47 components (excluding preferred stocks) of the KOSPI pharmaceutical index shrank by nearly KRW 6 trillion.
According to the Korea Exchange, stock prices of 40 out of 47 constituent stocks of the KOSPI pharmaceutical index fell in February, and eight of them recorded double-digit declines.
Among them, the stock prices of Daewoong Pharmaceutical and Daewoong both declined more than 20% due to the loss of the botulinum toxin strain lawsuit.
Shares of Gene One Life Science and Il Dong Holdings also fell more than 15%, and BioNote, Kyongbo Pharmaceutical, Bukwang Pharmaceutical, and Celltrion saw double-digit declines.
Nearly half of the KOSPI pharmaceutical index’s components, 23 stocks, including Yungjin Pharm., Daewon Pharmaceutical, Il Dong Pharmaceutical, Dong-A ST, PharmGen Science, Pharmicell, SK Bioscience, Green Cross, Shin Poong Pharmaceutical, Kukje Pharma, Boryung Pharmaceutical, Jeil Pharmaceutical, Samjin Pharmaceutical, Samil Pharmaceutical, and HanAll Biopharma saw their shares decrease by more than 5%.
Moreover, shares of Hana Pharm, Kwang Dong Pharmaceutical, Myungmoon Pharmaceutical, Dong Wha Pharm, Handok, Samsung Pharmaceutical, Chong Kun Dang Pharmaceutical, Aprogen Pharmaceuticals, Reyon Pharmaceutical, Samsung Biologics, Yuyu Pharma, CKD Bio, Chong Kun Dang Holdings, Korea United Pharm., Il-Yang Pharmaceutical, Whanin Pharmaceutical, and ORIENTBIO fell from the end of the previous month as well.
On the other hand, despite the stagnant performance of pharmaceutical stocks, Ilsung Pharmaceutical's share soared 33.3%, the only one with double-digit growth.
JW Life Science, JW Pharmaceutical, Dongsung Pharmaceutical, Yuhan Corporation, Hanmi Pharmaceutical, and Hyundai Pharmaceutical’s shares also rose from the end of the previous month, but the increase did not exceed 5%.
As the KOSPI pharmaceutical index fell into a slump, the market capitalization shrank by KRW 5.7076 trillion to KRW 105.8562 trillion in one month.
Celltrion’s market capitalization decreased the most by KRW 2.3071 trillion during this period, followed by Samsung Biologics by KRW 1.423 trillion.
The market capitalization of seven stocks fell more than KRW 100 billion, Daewoong Pharmaceutical by KRW 412.5 billion, SK Bioscience by KRW407 billion, Daewoong by KRW 291.9 billion, Green Cross by KRW 106.3 billion, and Gene One Life Science by KRW 103.4 billion.
There were no stocks whose market capitalization increased by more than KRW 100 billion in this period, while Ilsung Pharmaceutical saw the largest increase of KRW 75.8 billion.
As of 28 Feb., Samsung Biologics had the largest market cap of KRW 55.175 trillion, followed by Celltrion of KRW 20.477 trillion.
SK Bioscience fell to 5.3518 trillion, followed by Yuhan Corporation with KRW 4.389 trillion and Hanmi Pharmaceutical with KRW 3.2536 trillion.
Green Cross maintained the KRW 1 trillion mark with KRW 1.4 trillion, Daewoong Pharmaceutical with 1.3522 KRW trillion, and Shin Poong Pharmaceutical with KRW 1.274 trillion, but Daewoong and Chong Kun Dang Pharmaceutical retreated from the KRW 1 trillion mark.
